Literature DB >> 31632767

Does osimertinib treatment discriminate young patients?

Cheng Ji1, Chongke Zhong2, Shi-Yong Sun3.   

Abstract

Entities:  

Year:  2019        PMID： 31632767      PMCID： PMC6783796          DOI： 10.21037/jtd.2019.08.118

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  12 in total

1.  Overcoming resistance to targeted therapy for lung cancer.

Authors:  Ramaswamy Govindan
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

2.  Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.

Authors:  Isamu Okamoto; Satoshi Morita; Naoki Tashiro; Fumio Imamura; Akira Inoue; Takashi Seto; Nobuyuki Yamamoto; Yuichiro Ohe; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lung Cancer       Date:  2018-01-09       Impact factor: 5.705

3.  Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.

Authors:  Kenichi Suda; Isao Murakami; Tatsuya Katayama; Kenji Tomizawa; Hirotaka Osada; Yoshitaka Sekido; Yoshihiko Maehara; Yasushi Yatabe; Tetsuya Mitsudomi
Journal:  Clin Cancer Res       Date:  2010-11-09       Impact factor: 12.531

Review 4.  Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?

Authors:  Giandomenico Roviello; Laura Zanotti; Maria Rosa Cappelletti; Angela Gobbi; Martina Dester; Giovanni Paganini; Chiara Pacifico; Daniele Generali; Raheleh Roudi
Journal:  Clin Exp Med       Date:  2017-04-08       Impact factor: 3.984

5.  Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

Authors:  Suresh S Ramalingam; James C-H Yang; Chee Khoon Lee; Takayasu Kurata; Dong-Wan Kim; Thomas John; Naoyuki Nogami; Yuichiro Ohe; Helen Mann; Yuri Rukazenkov; Serban Ghiorghiu; Daniel Stetson; Aleksandra Markovets; J Carl Barrett; Kenneth S Thress; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2017-08-25       Impact factor: 44.544

6.  Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

Authors:  Catherine A Eberlein; Daniel Stetson; Aleksandra A Markovets; Katherine J Al-Kadhimi; Zhongwu Lai; Paul R Fisher; Catherine B Meador; Paula Spitzler; Eiki Ichihara; Sarah J Ross; Miika J Ahdesmaki; Ambar Ahmed; Laura E Ratcliffe; Elizabeth L Christey O'Brien; Claire H Barnes; Henry Brown; Paul D Smith; Jonathan R Dry; Garry Beran; Kenneth S Thress; Brian Dougherty; William Pao; Darren A E Cross
Journal:  Cancer Res       Date:  2015-04-13       Impact factor: 12.701

7.  Clinical significance of age at diagnosis among young non-small cell lung cancer patients under 40 years old: a population-based study.

Authors:  Mina Liu; Xuwei Cai; Wen Yu; Changxing Lv; Xiaolong Fu
Journal:  Oncotarget       Date:  2015-12-29

8.  Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors.

Authors:  Shang-Gin Wu; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang; Jin-Yuan Shih
Journal:  ERJ Open Res       Date:  2017-07-12

9.  Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Yasuhiro Kato; Yukio Hosomi; Kageaki Watanabe; Makiko Yomota; Shoko Kawai; Yusuke Okuma; Kaoru Kubota; Masahiro Seike; Akihiko Gemma; Tatsuru Okamura
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

10.  Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.

Authors:  Puyu Shi; You-Take Oh; Guojing Zhang; Weilong Yao; Ping Yue; Yikun Li; Rajani Kanteti; Jacob Riehm; Ravi Salgia; Taofeek K Owonikoko; Suresh S Ramalingam; Mingwei Chen; Shi-Yong Sun
Journal:  Cancer Lett       Date:  2016-07-19       Impact factor: 8.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.